PAVmed (PAVM) Q3 2024 earnings summary

Executive summary

• Completed a strategic transformation with the deconsolidation of Lucid Diagnostics and restructuring of convertible debt, positioning as a diversified life sciences entity with independently financed subsidiaries.

• Achieved record Q3 2024 revenue for Lucid Diagnostics' EsoGuard, up 20% quarter-over-quarter, and advanced Medicare coverage submission.

• Veris Health completed a pilot with Ohio State's James Cancer Center and secured a $1.8M NIH grant for its cancer care platform.

• Ongoing capital raise and strategic partnership discussions are underway, with a focus on stabilizing subsidiaries and expanding market initiatives.

• PMX incubator is seeking direct financing for PortIO device development and clinical trials.

Financial highlights

• Q3 2024 revenue rose to $1.0M–$1.2M, a 20% sequential increase, with year-to-date revenue reaching $3.0M.

• Net income attributable to common stockholders was $64.3M for Q3 2024, driven by a $72.3M gain from Lucid deconsolidation; basic EPS $6.43, diluted EPS $1.44.

• Adjusted non-GAAP loss narrowed to $5.4M, or $(0.54) per share, with operating expenses at $12.6M and non-GAAP operating expenses at $10.1M.

• Cash and cash equivalents declined sharply to $0.8M at quarter-end.

• Senior Secured Convertible Notes reduced to $32.1M from $44.0M quarter-over-quarter.

Outlook and guidance

• Operating expenses expected to remain steady, with increases tied to direct financing for Veris and PortIO; Veris implantable device development estimated at $2M over 6–8 months, PortIO at $4M over 12 months.

• Management expects continued recurring losses and negative cash flows in the near term, with ongoing operations dependent on increasing revenues and raising additional capital.

• Veris Health's 510(k) FDA submission may shift into the second half of 2025 due to financing delays.

• Substantial doubt exists about the ability to continue as a going concern over the next 12 months without new financing.

• PAVmed has until January 31, 2025, to regain Nasdaq compliance through a $25M debt-for-equity exchange, pending stockholder approval.